Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Membrane depolarization is implicated in the activation of the NLRP3 inflammasome. Downregulation of endothelial Ca2+-activated K+channels type 2.3 (KCa2.3) and endothelin-1 (ET-1) upregulation in the corpus cavernosum (CC) are associated with erectile dysfunction. We hypothesized that opening KCa2.2/2.3 channels could reverse erectile dysfunction and NLRP3 activation in hypertensive DOCA/salt mice. Methods: Hypertension was induced in mice using a DOCA/salt model, with unilaterally nephrectomized mice as controls; blood pressure was measured by tail-cuff. Intracavernous pressure (ICP) and CC reactivity were assessed. Western blot analysis for KCa2.3, caspase-1, and interleukin-1β (IL-1β) was performed. Endothelial cells from erectile tissue were isolated and stimulated with ET-1, and KCa2.2/2.3-dependent currents were evaluated via voltage-clamp electrophysiology. Results: DOCA/salt mice exhibited impaired erectile function, increased pro-caspase-1 and caspase-1 expression, and reduced relaxations induced by acetylcholine (ACh), sodium nitroprusside (SNP), and electrical field stimulation (EFS). Treatment with either the endothelin receptor antagonist bosentan or the KCa2.2/2.3 channel opener NS13001 reversed these dysfunctions and reduced ET-1-induced NLRP3 activation in DOCA/salt mice. NS13001 also restored the decreased current observed in primary endothelial cells exposed to ET-1. Apamin, a KCa2.2/2.3 channel blocker, inhibited erectile responses in unilaterally nephrectomized mice and restored erectile responses in DOCA mice. Apamin did not affect EFS-, ACh-, or SNP-induced relaxation in CC from hypertensive DOCA/salt mice. Conclusion: NS13001 reversed ET-1-induced NLRP3 activation and erectile dysfunction in DOCA/salt mice, suggesting that KCa2.2/2.3 channel modulation may restore erectile function in hypertension-related diseases.
Membrane depolarization is implicated in the activation of the NLRP3 inflammasome. Downregulation of endothelial Ca2+-activated K+channels type 2.3 (KCa2.3) and endothelin-1 (ET-1) upregulation in the corpus cavernosum (CC) are associated with erectile dysfunction. We hypothesized that opening KCa2.2/2.3 channels could reverse erectile dysfunction and NLRP3 activation in hypertensive DOCA/salt mice. Methods: Hypertension was induced in mice using a DOCA/salt model, with unilaterally nephrectomized mice as controls; blood pressure was measured by tail-cuff. Intracavernous pressure (ICP) and CC reactivity were assessed. Western blot analysis for KCa2.3, caspase-1, and interleukin-1β (IL-1β) was performed. Endothelial cells from erectile tissue were isolated and stimulated with ET-1, and KCa2.2/2.3-dependent currents were evaluated via voltage-clamp electrophysiology. Results: DOCA/salt mice exhibited impaired erectile function, increased pro-caspase-1 and caspase-1 expression, and reduced relaxations induced by acetylcholine (ACh), sodium nitroprusside (SNP), and electrical field stimulation (EFS). Treatment with either the endothelin receptor antagonist bosentan or the KCa2.2/2.3 channel opener NS13001 reversed these dysfunctions and reduced ET-1-induced NLRP3 activation in DOCA/salt mice. NS13001 also restored the decreased current observed in primary endothelial cells exposed to ET-1. Apamin, a KCa2.2/2.3 channel blocker, inhibited erectile responses in unilaterally nephrectomized mice and restored erectile responses in DOCA mice. Apamin did not affect EFS-, ACh-, or SNP-induced relaxation in CC from hypertensive DOCA/salt mice. Conclusion: NS13001 reversed ET-1-induced NLRP3 activation and erectile dysfunction in DOCA/salt mice, suggesting that KCa2.2/2.3 channel modulation may restore erectile function in hypertension-related diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.